Catalog No.
DHG62601
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Mouse
Isotype
Fab-G1-kappa
Clonality
Monoclonal
Target
5T4, TPBG, WAIF1, M6P1, 5T4 oncofetal trophoblast glycoprotein, Trophoblast glycoprotein, 5T4 oncofetal antigen, 5T4 oncotrophoblast glycoprotein, Wnt-activated inhibitory factor 1
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
Q13641
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
ABR-217620, ANYARA, TTS CD3, CAS: 676258-98-3
Clone ID
Naptumomab
Naptumomab estafenatox: a new immunoconjugate, PMID: 20053143
Naptumomab estafenatox: targeted immunotherapy with a novel immunotoxin, PMID: 24445502
Naptumomab estafenatox, an engineered antibody-superantigen fusion protein with low toxicity and reduced antigenicity, PMID: 20463598
A Randomized Phase II/III Study of Naptumomab Estafenatox + IFNα versus IFNα in Renal Cell Carcinoma: Final Analysis with Baseline Biomarker Subgroup and Trend Analysis, PMID: 26851187
Immunological response and overall survival in a subset of advanced renal cell carcinoma patients from a randomized phase 2/3 study of naptumomab estafenatox plus IFN-α versus IFN-α, PMID: 25669986
Antibodies to watch in 2013: Mid-year update, PMID: 23727858
Which are the antibodies to watch in 2013?, PMID: 23254906
Phase I dose escalation, pharmacokinetic and pharmacodynamic study of naptumomab estafenatox alone in patients with advanced cancer and with docetaxel in patients with advanced non-small-cell lung cancer, PMID: 19636016
Gateways to clinical trials, PMID: 18193114
Antibody-based therapeutics to watch in 2011, PMID: 21051951
The tumor targeted superantigen ABR-217620 selectively engages TRBV7-9 and exploits TCR-pMHC affinity mimicry in mediating T cell cytotoxicity, PMID: 24194959
For research use only. Not for human or drug use.
